TY  - RPRT
TI  - Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
AU  - Jose L. Jimenez
AU  - Mourad Tighiouart
AU  - Mauro Gasparini
PY  - 2018
DO  - 10.1002/bimj.201700166
UR  - https://arxiv.org/abs/1709.00918
ID  - 1709.00918
ER  -